Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Arcus Biosciences (RCUS) over the last 9 years, with Dec 2024 value amounting to $277.0 million.

  • Arcus Biosciences' Cash from Financing Activities fell 83.33% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.0 million, marking a year-over-year decrease of 29.08%. This contributed to the annual value of $277.0 million for FY2024, which is 739.39% up from last year.
  • Per Arcus Biosciences' latest filing, its Cash from Financing Activities stood at $277.0 million for FY2024, which was up 739.39% from $33.0 million recorded in FY2023.
  • Over the past 5 years, Arcus Biosciences' Cash from Financing Activities peaked at $439.0 million during FY2020, and registered a low of $33.0 million during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $33.0 million (2023), whereas its average is $114.3 million.
  • As far as peak fluctuations go, Arcus Biosciences' Cash from Financing Activities skyrocketed by 38,991.72% in 2020, and later slumped by 86.08% in 2022.
  • Yearly analysis of 5 years shows Arcus Biosciences' Cash from Financing Activities stood at $439.0 million in 2020, then plummeted by 46.01% to $237.0 million in 2021, then tumbled by 86.08% to $33.0 million in 2022, then remained steady at $33.0 million in 2023, then skyrocketed by 739.39% to $277.0 million in 2024.